Resources
129 Results (showing 31 - 40)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 12/15/2020 (updated 4/3/2024)
Region 4 RCORP grantees share their experiences.
Posted 11/4/2020 (updated 4/3/2024)
This brief seeks to further the limited research, policy, and practice on substance use coercion and to increase awareness about this issue among relevant stakeholders.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 8/25/2021 (updated 4/2/2024)
Created by the Association of State and Provincial Psychology Boards (ASPPB), the Psychology
Interjurisdictional Compact (PSYPACT) is an interstate compact that facilitates the practice of
psychology using telecommunications technologies (telepsychology) and/or
temporary in-person, face-to-face psychological practice.
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.